Stock ANAB ANAPTYSBIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News AnaptysBio, Inc.

Equities

ANAB

US0327241065

Real-time Estimate Cboe BZX
Other stock markets
 12:18:07 2024-06-14 pm EDT 		5-day change 1st Jan Change
23.72 USD -2.19% Intraday chart for AnaptysBio, Inc. +0.81% +10.27%
May. 09 AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 09 Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
GL
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
GL
Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis
CI
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
GL
Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target
MT
Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target
MT
JPMorgan Adjusts Price Target on AnaptysBio to $28 From $30, Maintains Neutral Rating
MT
AnaptysBio, Inc.(NasdaqGS:ANAB) added to S&P Biotechnology Select Industry Index
CI
North American Morning Briefing : Stock Futures -2-
DJ
AnaptysBio Shares Jump on Upgrade by Wedbush
MT
Wedbush Upgrades AnaptysBio to Outperform From Neutral, Says Derivative, Clinical Catalysts to Drive Shares Higher; Raises PT to $34 From $20
MT
AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
GL
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
AQ
BTIG Initiates Coverage on AnaptysBio With Buy Rating, $55 Price Target
MT
AnaptysBio Shares Climb as Piper Sandler Starts Coverage With Overweight Rating
MT
Piper Sandler Initiates AnaptysBio at Overweight Rating With $80 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANAB Stock
  4. News AnaptysBio, Inc.